1-(4-fluoro2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid | 1195782-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(4-fluoro2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
• 英文别名: 1-(4-Fluoro-2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid；1-(4-fluoro-2-methylphenyl)-2-oxopyridine-3-carboxylic acid
• CAS: 1195782-67-2
• 化学式: C₁₃H₁₀FNO₃
• 分子量: 247.226
• InChiKey: WTNTUNZHFLEFMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-fluoro2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 在 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 1-(4-fluoro-2-methylphenyl)-N-(3-fluoro-4-(6-(4-methoxybenzylamino) pyrimidin-4-yloxy)phenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
  参考文献：
  名称：

  New aminopyrimidine derivatives as inhibitors of the TAM family

  摘要：

  In this study, we describe the synthesis of new pyrimidine analogs of BMS-777607, a potent and selective inhibitor of Met kinase. Inhibition of Met and Axl remained high whereas inhibition of Tyro3 and Mer decreased to some extend. The preferential moderate inhibition of the non-phosphorylated form of Abl1 of some derivatives suggests that they behave as type II inhibitors. This hypothesis was confirmed by docking studies into the structure of Met (3F82) and in a Tyro3 model where key interactions with the hinge region, the DFG-out motif and the allosteric pocket explain this inhibition. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.10.037
• 作为产物：
  描述：

  4-氟-2-甲基苯胺 在 水 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 1-(4-fluoro2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION

  摘要：

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。

  公开号：

  WO2009136663A1

文献信息

• [EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009136663A1

  公开（公告）日：2009-11-12

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其用途。本发明涉及本说明书中所定义的符号表示的化合物，或其盐。
• FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
  申请人：Miyamoto Naoki

  公开号：US20110046169A1

  公开（公告）日：2011-02-24

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强大的激酶抑制活性的熔合杂环衍生物及其使用。本发明涉及一种由式子所表示的化合物，其中每个符号如本说明书中所定义的，或其盐。
• Fused heterocyclic derivatives and use thereof
  申请人：Miyamoto Naoki

  公开号：US08445509B2

  公开（公告）日：2013-05-21

  The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有强烈激酶抑制活性的融合杂环衍生物及其使用。本发明涉及一种由下式表示的化合物，其中每个符号如本说明书所定义，或其盐。
• US8445509B2
  申请人：——

  公开号：US8445509B2

  公开（公告）日：2013-05-21
• New aminopyrimidine derivatives as inhibitors of the TAM family
  作者：Ténin Traoré、Andrea Cavagnino、Nicolas Saettel、François Radvanyi、Sandrine Piguel、Isabelle Bernard-Pierrot、Véronique Stoven、Michel Legraverend

  DOI：10.1016/j.ejmech.2013.10.037

  日期：2013.12

  In this study, we describe the synthesis of new pyrimidine analogs of BMS-777607, a potent and selective inhibitor of Met kinase. Inhibition of Met and Axl remained high whereas inhibition of Tyro3 and Mer decreased to some extend. The preferential moderate inhibition of the non-phosphorylated form of Abl1 of some derivatives suggests that they behave as type II inhibitors. This hypothesis was confirmed by docking studies into the structure of Met (3F82) and in a Tyro3 model where key interactions with the hinge region, the DFG-out motif and the allosteric pocket explain this inhibition. (C) 2013 Elsevier Masson SAS. All rights reserved.